# A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine

> **NCT00539396** · PHASE2 · COMPLETED · sponsor: **Mannkind Corporation** · enrollment: 110 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Technosphere Insulin

## Key facts

- **NCT ID:** NCT00539396
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2009-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00539396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00539396, "A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00539396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*